Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
Sivas, A., et al., Prooxidant activities of alpha-lipoic acid on oxidative protein damage in the aging rat heart muscle
Key regulatory milestones: Phase 2 results published in NEJM (2023) Phase 3 TRIUMPH-4 topline results reported December 11, 2025 (28.7% mean weight loss at 12 mg / 68 weeks, approximately 71 lb at cohort starting weight); additional trials reading out 2026 (NCT05929066, NCT06070792) FDA approval window: still pending the full Phase 3 package and regulatory review Current non-trial access is research or grey-market, not an approved prescription pathway
Furthermore, patients should be advised to avoid contact with eyes and mucous membranes when using this nasal spray
Yet, whether potential protection conferred by isothiocyanates via the Nrf2-dependent pathway is diminished in individuals carrying GST null variants is currently unknown
-500x500.jpg)
